Research on the drug, known as DYR533, was conducted at the the University of Arizona R. Ken Coit College of Pharmacy and BIO5 Institute, in partnership with the Biodesign Institute in Phoenix.
ASU researcher Travis Dunckley and University of Arizona Professor Christopher Hulme and their colleagues have developed a candidate drug they hope may successfully block the development or advancement of Alzheimer’s disease in Down syndrome patients.